Adenoassociated viral mediated persistant anti-VEGF therapy for ovarian cancer
US10946094B2 · kind B2 · utility
1Cited by
8References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 24, 2016 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Feb 24, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2750/14143
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides a method of treating ovarian cancer in a patient by administering to the patient an adeno-associated virus (AAV) vector encoding an anti-VEGF antibody or antigen binding fragment thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.